News | February 08, 2024
MIRA Pharmaceuticals announces collaboration with Pharmaseed
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The registered capital of the newly founded company is € 50 million
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
An accomplished R&D leader and champion of the application of AI to drug discovery
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Collaboration streamlines patient access to oncology clinical trials
Subscribe To Our Newsletter & Stay Updated
